Investors

NASDAQ: STEM

Listed on the NASDAQ Market since 1992, we are committed to balancing our standards of scientific rigor and clinical integrity with our corporate imperatives of value creation and long-term business sustainability.

Corporate Profile

StemCells, Inc. is poised to be among the first to market stem cell-based therapeutic products to treat diseases and disorders of the central nervous system (CNS). The Company’s proprietary HuCNS-SC® (purified human neural stem cells) platform technology is currently in clinical development for spinal cord injury (SCI) and age-related macular degeneration (AMD). Expandable and bankable, HuCNS-SC cells can ultimately be "manufactured" at commercial-scale as "stem cells in a bottle," then distributed for patient doses, much like an off-the-shelf pharmaceutical product. More >>

Learn more about What Sets Us Apart.


StemCells, Inc. has been listed on the NASDAQ Market since 1992.
Letter to Investors
January 2015  Letter to Investors from CEO Martin McGlynn
Recent News
07/01/15StemCells, Inc. to Participate at Cantor Fitzgerald's Inaugural Healthcare Conference
Management Will Present an Update on the Company's Programs, Pipeline and Operations NEWARK, Calif., July 1, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) announced today that management will make a presentation on the Company's programs, pipeline and operations at Cantor Fitzgerald's Inaugural Healthcare Conference. Management is scheduled to speak at 11:45 a.m. Eastern Standard Time on Wednesday, July 8, at the Le Parker Meridian Hotel, located at 119 W. 56th Street in New York City.... 
Printer Friendly Version
06/26/15StemCells, Inc. Reports Top Line Results for Its Phase I/II Study in Dry Age Related Macular Degeneration
Initiates Phase II Proof-of-Concept Radiant(TM) Study in AMD NEWARK, Calif., June 26, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ:STEM), a leading stem cell company developing novel cell-based therapeutics for treating diseases and disorders of the central nervous system, announced today that Dr. Stephen Huhn, its Vice President of Clinical Research and Chief Medical Officer, presented an overview of the Company's clinical translation efforts to date, including a summary of the safety and ... 
Printer Friendly Version
06/18/15StemCells, Inc.'s Phase II Pathway Study for Cervical Spinal Cord Injury Approved by Health Canada
NEWARK, Calif., June 18, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system diseases and disorders, announced today that Health Canada has authorized the Company to expand its Phase II clinical trial for chronic cervical spinal cord injury into Canada. The Pathway Study™ is designed to assess the efficacy of the Company's proprietary HuCNS-SC® platform technology (purified h... 
Printer Friendly Version
06/04/15StemCells, Inc. Announces Commencement of the Second Cohort of the Pathway(TM) Study in Cervical Spinal Cord Injury
Phase II Study Designed to Assess the Potential of Human Neural Stem Cells to Restore Motor Function NEWARK, Calif., June 4, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system diseases and disorders, announced today that it has enrolled its first subject in Cohort 2 of its Phase II Pathway Study. The study is designed to assess the efficacy of the Company's proprietary HuCN... 
Printer Friendly Version
More >>
Upcoming Events
DateTitle
07/08/15
StemCells, Inc. at the Cantor Fitzgerald's Inaugural Healthcare Conference
LocationLe Parker Meridian Hotel
119 W. 56th Street
New York City, NY
Presentations
DateTitle
03/19/15
Download Documentation StemCells, Inc. at the Wall Street Analyst Forum 25th Annual Institutional Investor Conference
Get help downloading or viewing the above file types
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever StemCells, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Enter your e-mail address here:

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Stock Quote
STEM (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$0.53
Change (%) Stock is Down 0.01 (3.64%)
Volume811,882
Data as of 07/02/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Analyst Coverage

Click here for a list of analysts covering StemCells, Inc.

Primary IR Contact

Greg Schiffman
CFO
StemCells, Inc.
7707 Gateway Blvd
Newark, CA 94560
Phone: 510.456.4128
Fax: 650.475.3101
Contact by e-mail



Investor Tools
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
Financial Tear SheetFinancial Tear Sheet